| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $22.8M | +180.2% |
| SG&A Expense | $15.8M | +165.2% |
| Operating Income | -$38.6M | -173.9% |
| Interest Expense | $0 | -100.0% |
| Pre-tax Income | -$41.7M | -139.3% |
| Income Tax | $0 | — |
| Net Income | -$41.7M | -139.3% |
| EPS (Basic) | -$3.71 | +52.6% |
| EPS (Diluted) | -$3.71 | +52.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $58.0M | -30.6% |
| Accounts Receivable | $0 | -100.0% |
| Current Assets | $59.0M | -33.1% |
| Total Assets | $59.6M | -32.5% |
| Current Liabilities | $11.3M | -5.8% |
| Total Liabilities | $31.6M | +23.2% |
| Stockholders' Equity | $28.0M | -55.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$25.0M | -130.7% |
| Financing Cash Flow | -$660K | -100.8% |